Literature DB >> 2228527

The use of cyclosporin A in adult nephrotic syndrome: nine cases and literature review.

A Green1, Y O'Meara, J Sheehan, M Carmody, G Doyle, J Donohoe.   

Abstract

Nine adult patients with resistant nephrotic syndrome were treated with cyclosporin A (CyA). All had failed to respond to high dose corticosteroids with or without cyclophosphamide. Three patients had minimal change disease, 3 had focal sclerosing glomerulosclerosis (FSGS), 2 had mesangiocapillary GN, and one had membranous nephropathy. The mean age of the patients was 26.4 years (range 16 to 39 years). CyA was given orally twice daily at a mean dose of 6.7 mg/kg/24 hours (range 6-10 mg/kg/24 hours). Four patients achieved full remission, two patients went into partial remission and three failed to respond. Two patients developed clinical nephrotoxicity, which reversed on dose reduction or cessation of CyA. All 3 patients with minimal change disease who responded subsequently relapsed after stopping CyA, but remitted rapidly on reintroduction of the drug. We suggest that the mode of action of CyA in nephrotic syndrome may be related to intra-renal vasoconstriction in addition to its direct immunosuppressive effect. In this limited series, we found that CyA can be an effective therapy for otherwise refractory nephrotic syndrome, although relapse on withdrawal of CyA may well be a significant clinical problem.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2228527     DOI: 10.1007/bf02937238

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  22 in total

1.  Remission of idiopathic nephrotic syndrome after treatment with cyclosporin A.

Authors:  A Meyrier; P Simon; G Perret; M C Condamin-Meyrier
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-22

Review 2.  The pathogenesis of minimal change nephropathy.

Authors:  N P Mallick
Journal:  Clin Nephrol       Date:  1977-03       Impact factor: 0.975

Review 3.  Treatment with cyclosporin of patients with idiopathic nephrotic syndrome.

Authors:  A Meyrier
Journal:  Springer Semin Immunopathol       Date:  1987

4.  Pathogenesis of lipoid nephrosis: a disorder of T-cell function.

Authors:  R J Shalhoub
Journal:  Lancet       Date:  1974-09-07       Impact factor: 79.321

Review 5.  Pathogenetic mechanisms of nephrotoxicity: insights into cyclosporine nephrotoxicity.

Authors:  H D Humes; N M Jackson; R P O'Connor; D A Hunt; M D White
Journal:  Transplant Proc       Date:  1985-08       Impact factor: 1.066

6.  Suppression of plasma renin activity by cyclosporine.

Authors:  J P Bantle; R J Boudreau; T F Ferris
Journal:  Am J Med       Date:  1987-07       Impact factor: 4.965

7.  Effect of cyclosporine A on mercury-induced autoimmune glomerulonephritis in the Brown Norway rat.

Authors:  D Baran; B Vendeville; M C Vial; C Cosson; C Bascou; P Teychenne; P Druet
Journal:  Clin Nephrol       Date:  1986       Impact factor: 0.975

8.  Cyclosporin A in steroid-sensitive nephrotic syndrome with frequent relapses.

Authors:  M K Chan; I K Cheng
Journal:  Postgrad Med J       Date:  1987-09       Impact factor: 2.401

9.  Cyclosporin in the treatment of steroid-responsive and steroid-resistant nephrotic syndrome in adults.

Authors:  E R Maher; P Sweny; M Chappel; Z Varghese; J F Moorhead
Journal:  Nephrol Dial Transplant       Date:  1988       Impact factor: 5.992

10.  Glomerulonephritis in NZB/W mice: therapeutic effect of cyclosporine.

Authors:  H C Gunn; B Ryffel
Journal:  Clin Nephrol       Date:  1986       Impact factor: 0.975

View more
  1 in total

Review 1.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.